Adlai Nortye's (ANL) Sell (E+) Rating Reaffirmed at Weiss Ratings

Key Points

• Weiss Ratings has reaffirmed a "sell (e+)" rating for Adlai Nortye (ANL), indicating continued skepticism about the company's stock performance.
• Adlai Nortye's stock price increased by $0.05 to $1.78 during recent trading, but remains significantly below its 1-year high of $3.89.
• The company is a clinical-stage biotechnology firm focused on developing cancer therapies, with its lead product AN2025 currently in Phase III trials targeting head and neck cancers.

Adlai Nortye (NASDAQ:ANL - Get Free Report)'s stock had its "sell (e+)" rating reissued by Weiss Ratings in a research note issued on Wednesday,Weiss Ratings reports.

Adlai Nortye Stock Performance

ANL traded up $0.05 during trading hours on Wednesday, hitting $1.78. 9,883 shares of the company's stock were exchanged, compared to its average volume of 11,186. Adlai Nortye has a 1-year low of $1.10 and a 1-year high of $3.89. The stock's 50-day moving average is $1.69 and its two-hundred day moving average is $1.74.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.